bullish
Samsung Biologics (207940 KS): Record-High Semi-Annual Revenue Exceeding KRW1 Trillion
366 Views29 Jul 2022 23:33
SUMMARY
- Samsung Biologics (207940 KS) achieved highest ever semi-annual revenue of KRW 1.62 trillion in H1 2022, with an operating profit of KRW346.1 billion, mainly driven by its contract manufacturing business.
- At the end of Q2, the company had an order book of $7.9 billion, entailing revenue visibility. Its new plant is on track to start operation in October.
- Samsung Bioepis has launched first ophthalogy biosimilar in the U.S. in June. Both the CDMO and biosimilar businesses are expected to clock solid annual revenue growth in 2022.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Samsung Biologics (207940 KS): Slow Start of 2023; Stronger Growth in H2; 2023 Guidance Raised27 Apr 2023
- Samsung Biologics (207940 KS): 2022 Revenue Surpassed KRW3T; Strong Growth Momentum to Continue31 Jan 2023
- Samsung Biologics (207940 KS): Near-Term Key Positive Catalysts07 Jan 2023
- Samsung Biologics (207940 KS): Record-High Semi-Annual Revenue Exceeding KRW1 Trillion29 Jul 2022
- Samsung Biologics (207940 KS): Well-Positioned to Leap Forward Without Biogen Deal20 Jan 2022
- Samsung Biologics Contract Manufacturing Deal with Moderna for COVID-19 Vaccines: Key Takeaways14 May 2021
x